Berends Maartje A M, Driessen Rieke J B, Langewouters Annechien M G, Boezeman Jan B, Van De Kerkhof Peter C M, De Jong Elke M G J
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
J Dermatolog Treat. 2007;18(2):76-83. doi: 10.1080/09546630601121086.
Since the beginning of 2005, etanercept and efalizumab are officially registered and reimbursed for the treatment of recalcitrant psoriasis in The Netherlands.
The evaluation of the efficacy, safety and adverse events of etanercept and efalizumab treatment in daily practice.
A prospective cohort study was carried out for patients treated with etanercept or efalizumab between February 2005 and March 2006.
Over the past 13 months 45 individuals were treated with etanercept and 17 subjects were treated with efalizumab. The cohort represented a high-need population. At week 12, 82% of the subjects treated with 2 x 50 mg etanercept/week and 71% of the subjects treated with 2 x 25 mg etanercept/week reached a PASI-50. Efficacy of etanercept treatment was comparable to the results of clinical trials. For efalizumab, efficacy in responding patients was also comparable to clinical trial data, but the percentage of dropouts was substantial. During biologic treatment, safety was preserved and mainly mild adverse events were reported.
Etanercept and efalizumab are effective and safe treatments of psoriasis, even in a high-need population. Etanercept was able to sustain the clinical improvement throughout 24 weeks, whereas efalizumab was not in 47% of subjects.
自2005年初起，依那西普和依法利珠单抗在荷兰正式注册并可报销用于治疗顽固性银屑病。
评估依那西普和依法利珠单抗在日常临床中的疗效、安全性及不良事件。
对2005年2月至2006年3月间接受依那西普或依法利珠单抗治疗的患者进行一项前瞻性队列研究。
在过去13个月中，45例患者接受了依那西普治疗，17例患者接受了依法利珠单抗治疗。该队列代表了高需求人群。在第12周时，每周接受2×50mg依那西普治疗的患者中有82%达到银屑病面积和严重程度指数（PASI）改善50%，每周接受2×25mg依那西普治疗的患者中有71%达到该标准。依那西普的治疗效果与临床试验结果相当。对于依法利珠单抗，有反应患者的疗效也与临床试验数据相当，但退出率较高。在生物治疗期间，安全性良好，主要报告的是轻度不良事件。
依那西普和依法利珠单抗治疗银屑病有效且安全，即使是在高需求人群中。依那西普在整个24周内都能维持临床改善，而依法利珠单抗在47%的患者中未能做到。
